Nadav Kidron
Nadav Kidron, Esq
Chief Executive Officer, President & Director
Mr. Kidron serves as Chief Executive Officer & Director of Oramed Pharmaceuticals, which he co-founded in 2006.

Mr. Kidron is an entrepreneur whose experience includes senior executive roles in a wide range of industries.

He co-founded Entera Bio as a joint venture formed by Oramed and DNA Biomedical Solutions. He is a member of the IATI Board, and an international lecturer on Israel’s entrepreneurial culture and the country’s roots as an oasis of innovative ideas.

He holds a bachelor’s degree in law and an international master’s in business administration, both from Bar-Ilan University in Israel. Mr. Kidron is a fellow of the Merage Business Executive Leadership Program and a member of the Israeli Bar Association.

Miriam Kidron, Ph.D
Chief Scientific Officer & Director
Dr. Kidron serves as Chief Scientific Officer and Director of Oramed Pharmaceuticals, which she co-founded in 2006.

Dr. Kidron is a pharmacologist and biochemist, who earned her PhD in biochemistry from the Hebrew University of Jerusalem.

For close to 20 years, Dr. Kidron has been a senior researcher in the Diabetes Unit at Hadassah-Hebrew University Medical Center in Jerusalem, Israel, earning the Bern Schlanger Award for her work on diabetes research.

She was formerly a visiting professor at the Medical School at the University of Toronto and is a member of the American, European and Israeli Diabetes Associations.

Hilla Eisenberg, CPA
Chief Financial Officer
Ms. Eisenberg serves as Chief Financial Officer of Oramed Pharmaceuticals. She joined Oramed in 2016, and prior to her appointment as CFO served as the Company’s Finance Manager.

Prior to joining Oramed, she provided audit and accounting services at a certified public accounting firm in Israel and served as an auditor at PwC Israel (Kesselman & Kesselman) including a short secondment to PwC New York.

Ms. Eisenberg brings to Oramed very strong financial experience with an assortment of publicly traded and private companies.

Ms. Eisenberg holds a bachelor’s degree in accounting and economics from Tel-Aviv University and is a certified public accountant (CPA) in Israel.

Josh Hexter
Chief Operating Officer, VP Business Development
Mr. Hexter serves as Chief Operating Officer and Vice President of Business Development of Oramed Pharmaceuticals, which he joined in 2013.

He brings to Oramed more than 15 years of prominent leadership, business development, operations know-how and management in the life science sector.

Mr. Hexter was most recently Executive Director of Corporate In-Licensing at BioLineRx (NASDAQ: BLRX).

Prior to joining BioLineRx, he worked in private equity and venture capital where he served as CEO of a VC-backed startup. As CEO of Biosensor Systems Design, Mr. Hexter was instrumental in shaping the company’s strategic focus and in forging business development agreements with Fortune 100 companies in the areas of food safety, medical diagnostics and homeland security.

Mr. Hexter earned a bachelor’s degree from the University of Wisconsin and a master’s degree in management from Boston University.

Dr. Ronald Law
Chief Strategy Officer
Dr. Law serves as Chief Strategy Officer for Oramed Pharmaceuticals.

He brings over 25 years academic and pharmaceutical industry experience in diabetes, cardiovascular disease, and obesity.

During his industry career at Takeda Pharmaceuticals, Dr. Law served in a variety of roles spanning US Medical Affairs, Global Medical Affairs, Corporate Strategic Planning, Global Scientific Affairs and Intelligence, and R&D External Innovation.

Prior to joining Takeda, Dr. Law was an Associate Professor of Medicine in the Endocrinology Division, UCLA School of Medicine. Dr. Law received a PhD in Molecular Biology from UCLA and a JD from the Whittier College School of Law. He is a member of the American Diabetes Association and the American Heart Association.

Dr. Simon Bruce
VP Medical Affairs
Dr. Bruce serves as Vice President of Medical Affairs For Oramed Pharmaceuticals.

Dr Bruce has made important contributions to new product development and clinical therapeutics in diabetes and metabolism over the past 20 years. He has broad experience across all phases of clinical development and has been responsible for clinical development strategy and execution from pre-IND to first-in-human through Phase 3 planning, execution and filing.  He has led clinical development of multiple compounds in the metabolic and diabetes therapeutic areas including DPP4 and SGLT2 inhibitors, GLP-1 agonists, leptin and prandial insulins among others.

He has trained in Internal Medicine with sub-specialization in Endocrinology at the NIH.  He has held positions of increasing responsibility in both large pharmaceutical and small to medium sized biotech companies.  Most recently he served as Chief Medical Officer with Adocia Inc., working on an ultra-rapid insulin in collaboration with Eli Lilly.